Erika Hamilton
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Rastogi P, O'Shaughnessy J, Martín M, Boyle F, Cortes J, Rugo H, Goetz M, Hamilton E, Huang C, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, Andre V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. J Clin Oncol 2024:JCO2301994.
Jan 9, 2024Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Jan 9, 2024J Clin Oncol 2024:JCO2301994
Rastogi Priya, O'Shaughnessy Joyce, Martín Miguel, Boyle Frances, Cortes Javier, Rugo Hope S, Goetz Matthew P, Hamilton Erika, Huang Chiun-Sheng, Senkus Elzbieta, Tryakin Alexey, Cicin Irfan, Testa Laura, Neven Patrick, Huober Jens, Shao Zhimin, Wei Ran, Andre Valerie A M, Munoz Maria, San Antonio Belen, Shahir Ashwin, Harbeck Nadia, Johnston Stephen R D
nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer
Hamilton E, Chen Y, Zhang W, Huober J, Hegg R, Jerusalem G, Manikhas A, Petrakova K, Chen S, Ozyilkan O, Cortes J, Martín M. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer. Breast Cancer Res Treat 2022; 195:55-64.
Jul 12, 2022nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2- metastatic breast cancer
Jul 12, 2022Breast Cancer Res Treat 2022; 195:55-64
Hamilton Erika, Chen Yanyun, Zhang Wei, Huober Jens, Hegg Roberto, Jerusalem Guy, Manikhas Aleksey, Petrakova Katarina, Chen Shin-Cheh, Ozyilkan Ozgur, Cortes Javier, Martín Miguel
nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Hamilton E, Johnston E, Bear M, Hardebeck M, Lu Y, Chapman S, Huober J, Hegg R, Jerusalem G, Manikhas A, Petrakova K, Chen S, Ozyilkan O, Cortes J, Martín M. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. Clin Breast Cancer 2020
Sep 30, 2020nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer
Sep 30, 2020Clin Breast Cancer 2020
Hamilton Erika, Johnston Erica L, Bear Melissa M, Hardebeck Molly C, Lu Yi, Chapman Sonya C, Huober Jens, Hegg Roberto, Jerusalem Guy, Manikhas Aleksey, Petrakova Katarina, Chen Shin-Cheh, Ozyilkan Ozgur, Cortes Javier, Martín Miguel
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Johnston S, Huober J, Wardley A, Tolaney S, Cicin I, Smith I, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O'Shaughnessy J, Rastogi P, Cortes J, Neven P, Harbeck N, Hegg R, Toi M, Martín M, Shao Z, Zhang Q, Martinez Rodriguez J, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020; 38:3987-3998.
Sep 20, 2020Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Sep 20, 2020J Clin Oncol 2020; 38:3987-3998
Johnston Stephen R D, Huober Jens, Wardley Andrew, Tolaney Sara M, Cicin Irfan, Smith Ian C, Frenzel Martin, Headley Desirée, Wei Ran, San Antonio Belen, Hulstijn Maarten, Cox Joanne, O'Shaughnessy Joyce, Rastogi Priya, Cortes Javier, Neven Patrick, Harbeck Nadia, Hegg Roberto, Toi Masakazu, Martín Miguel, Shao Zhi Min, Zhang Qing Yuan, Martinez Rodriguez Jorge Luis, Campone Mario, Hamilton Erika, Sohn Joohyuk, Guarneri Valentina, Okada Morihito, Boyle Frances, monarchE Committee Members and Investigators